Revolution Medicines Inc.

31.33
-1.54 (-4.69%)
At close: Apr 04, 2025, 3:59 PM
31.05
-0.89%
After-hours: Apr 04, 2025, 04:49 PM EDT

Revolution Medicines Statistics

Share Statistics

Revolution Medicines has 185.91M shares outstanding. The number of shares has increased by 12.68% in one year.

Shares Outstanding 185.91M
Shares Change (YoY) 12.68%
Shares Change (QoQ) 1.95%
Owned by Institutions (%) 99.99%
Shares Floating 161.67M
Failed to Deliver (FTD) Shares 248
FTD / Avg. Volume 0.02%

Short Selling Information

The latest short interest is 16.59M, so 9.1% of the outstanding shares have been sold short.

Short Interest 16.59M
Short % of Shares Out 9.1%
Short % of Float 10.77%
Short Ratio (days to cover) 12.56

Valuation Ratios

The PE ratio is -12.23 and the forward PE ratio is -10.52. Revolution Medicines's PEG ratio is 1.69.

PE Ratio -12.23
Forward PE -10.52
PS Ratio 0
Forward PS 4.3
PB Ratio 3.24
P/FCF Ratio -12.92
PEG Ratio 1.69
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Revolution Medicines.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 14.2, with a Debt / Equity ratio of 0.06.

Current Ratio 14.2
Quick Ratio 14.2
Debt / Equity 0.06
Debt / EBITDA -0.2
Debt / FCF -0.24
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $0
Profits Per Employee $-1.12M
Employee Count 534
Asset Turnover 0
Inventory Turnover n/a

Taxes

Income Tax 753K
Effective Tax Rate -0.13%

Stock Price Statistics

The stock price has increased by 0.19% in the last 52 weeks. The beta is 1.37, so Revolution Medicines's price volatility has been higher than the market average.

Beta 1.37
52-Week Price Change 0.19%
50-Day Moving Average 39.61
200-Day Moving Average 44.46
Relative Strength Index (RSI) 26.5
Average Volume (20 Days) 1.41M

Income Statement

Revenue n/a
Gross Profit 0
Operating Income -689.52M
Net Income -600.09M
EBITDA -689.52M
EBIT n/a
Earnings Per Share (EPS) -3.58
Full Income Statement

Balance Sheet

The company has 543.06M in cash and 135.84M in debt, giving a net cash position of 407.22M.

Cash & Cash Equivalents 543.06M
Total Debt 135.84M
Net Cash 407.22M
Retained Earnings -1.74B
Total Assets 2.56B
Working Capital 2.16B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -557.44M and capital expenditures -10.31M, giving a free cash flow of -567.74M.

Operating Cash Flow -557.44M
Capital Expenditures -10.31M
Free Cash Flow -567.74M
FCF Per Share -3.38
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

RVMD does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for RVMD is $65.5, which is 109.1% higher than the current price. The consensus rating is "Buy".

Price Target $65.5
Price Target Difference 109.1%
Analyst Consensus Buy
Analyst Count 12
Stock Forecasts

Scores

Altman Z-Score 11.68
Piotroski F-Score 2